Cargando…

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals

OBJECTIVE: With the introduction of new therapies, hospitals have to plan spending limited resources in a cost-effective manner. To assist in identifying the optimal treatment for patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, budget impact modeling was us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortendahl, Jesse D, Pulgar, Sonia J, Mirakhur, Beloo, Cox, David, Bentley, Tanya GK, Phan, Alexandria T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566387/ https://www.ncbi.nlm.nih.gov/pubmed/28860831 http://dx.doi.org/10.2147/CEOR.S140866

Ejemplares similares

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database
por: Fisher, Maxine D., et al.
Publicado: (2018)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Hee Sung, et al.
Publicado: (2011)

A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors
por: Seo, Caroline, et al.
Publicado: (2022)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center
por: Jalbert, Jessica J., et al.
Publicado: (2020)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
por: Crabtree, Judy S.
Publicado: (2022)

Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms
por: Ramachandran, Anupama, et al.
Publicado: (2022)

Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
por: Shi, Chanjuan, et al.
Publicado: (2022)

Liver transplantation in gastroenteropancreatic neuroendocrine tumors
por: Fernandes, Eduardo de Souza M., et al.
Publicado: (2023)

Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
por: McClellan, Kristen, et al.
Publicado: (2022)

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
por: Nielsen, Kirstine, et al.
Publicado: (2020)

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
por: Lenotti, Elisa, et al.
Publicado: (2021)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
por: Dromain, Clarisse, et al.
Publicado: (2021)

Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program
por: Sevilla, Isabel, et al.
Publicado: (2016)

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
por: Bongiovanni, Alberto, et al.
Publicado: (2015)

Gastroenteropancreatic neuroendocrine tumors in children and young adults
por: Khanna, Geetika, et al.
Publicado: (2007)

Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors
por: Öberg, Kjell
Publicado: (2012)

Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
por: Kawasaki, Kenta, et al.
Publicado: (2018)

Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
por: Cives, Mauro, et al.
Publicado: (2020)

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot
por: Fernandez, Cornelius J, et al.
Publicado: (2021)

Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs
por: Li, Su-Chen, et al.
Publicado: (2015)

(225)Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
por: Rubira, Léa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_luivpjb1f84usue8u783hj54jd